ONCORAL
Oncoral in short
Oncoral is novel patented irinotecan chemotherapy tablet. With daily dosing, Oncoral has the potential to offer both efficacy and safety benefits to cancer patients compared to intravenous high-dose infusions at the hospital
Development plan – Phase 2 and onwards
The development plan is to conduct a Phase 2 study in gastric cancer and from there potential label expansion into other solid cancer indications.
Presentations (films)
Magnus Corfitzen - CEOOncoral strategic plans
Strategic plans for Oncoral and its potential role in as a novel chemotherapy tablet helping patients suffering from cancer
Carl Bjartmar – CMOOncoral development plan
Presentation of the unmet medical need to be filled by Oncoral as well as the clinical development plan
Prof. Jeff Evans - expert oncologistUnmet medical need within gastric cancer
Oncology expert Prof. Jeff Evans talks about the great unmet need to develop novel drugs for the treatment of gastric cancer. Jeff Evans forms part of Ascelia Pharma's Scientific Advisory Board for Oncoral.
Here you will find all the relevant documents for the day
Oncoral - CEO presentation
Download presentation from the CEO.
Oncoral - CMO presentation
Download presentation from Chief Medical Officer.
Oncology expert - Prof. Jeff Evans
Download presentation from Oncology Expert, Prof. Jeff Evans